Compare Dyne Therapeutics Inc. Common Stock (DYN) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while YieldMax TSLA Option Income Strategy ETF trades at $21.18 (market cap $675.95M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 4.2× YieldMax TSLA Option Income Strategy ETF's market cap, and YieldMax TSLA Option Income Strategy ETF is more actively traded (216,837 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and YieldMax TSLA Option Income Strategy ETF for 45 Days on average.
| DYN | TSLY | |
|---|---|---|
Market Cap | $2.86B | $675.95M |
Volume | 3,341,579 | 216,837 |
Sector | Health | Income / Options Overlay |
52-Week High | $26.78 | $43.35 |
52-Week Low | $14.60 | $20.49 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
TSLY trades at $22.11, down 0.58% with a bearish technical signal from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent news highlights concerns about underperformance relative to Tesla's stock gains. Technical indicators show neutral oscillators with key support at $22 and resistance at $23.
The outlook remains cautious as TSLY faces structural challenges capturing Tesla's upside while providing income. Investors should weigh the high dividend yield against potential capital erosion during Tesla rallies. Key risks include volatility regime changes and the ETF's option strategy limitations in strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
